Crossmark

Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors

Crossref DOI link: https://doi.org/10.1186/s12885-026-15616-z

Published Online: 2026-01-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Wen

Wu, Xuemei

Sun, Xiaorong

Wen, Jian

He, Xiaoli

Zhang, Mingzhou

Wang, Guansong

Xu, Zhi https://orcid.org/0000-0003-1199-6635
Funding

Funding for this research was provided by:

Chongqing Science and Health Joint Medical Research Project (2023QNXM045)

Chongqing Science and Health Joint Medical Research Project (2024GGXM001)

Chongqing Natural Science Foundation General Program (CSTB2024NSCQ-MSX1114)

Clinical Research Special Project of the Second Affiliated Hospital of Army Medical University (2024F030)
License Information

Text and Data Mining valid from 2026-01-23

Version of Record valid from 2026-02-18
More Information

Article History

Received: 8 November 2025

Accepted: 16 January 2026

First Online: 23 January 2026

Declarations

:

: This case was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The data collection was approved by the Ethics Committees of Army Medical University (2025-199-01). The authors ensure the confidentiality of patient data. Given the retrospective nature of the study and the use of de-identified clinical data, the requirement for informed consent was waived by the ethics committee.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below